Matthew Posard Buys 45,000 Shares of Nautilus Biotechnology
Matthew Posard increased his holdings in Nautilus Biotechnology with a 45,000-share purchase.
Key Points
- Matthew Posard increased his holdings in Nautilus Biotechnology by purchasing 45,000 shares on June 18, 2026.
- Shares of Nautilus Biotechnology traded near $2.31 on Tuesday, with recent insider buying activity boosting interest.
- A16Z Capital Management holds 17.65 million shares, while Vanguard Capital Management opened a new position with 2.55 million shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Matthew Posard has increased his holdings in Nautilus Biotechnology by purchasing 45,000 shares on June 18, 2026. This insider transaction reflects ongoing interest in the company among its leadership.
Insider Buying and Selling at Nautilus Biotechnology, Inc.
On June 18, 2026, several insiders, including Matthew Posard, purchased shares in Nautilus Biotechnology. Posard acquired 45,000 shares, as did other insiders such as Matthew McIlwain, Karen Akinsanya, Melissa Epperly, and Farzad Nazem. Sujal Patel, the CEO, President, and Secretary, bought 25,000 shares at an average price of $2.61 on March 4, 2026. These transactions were not conducted under Rule 10b5-1 plans.
Other Institutional Activity in Nautilus Biotechnology
Several institutional investors have made moves regarding their positions in Nautilus Biotechnology. A16Z Capital Management holds approximately 17.65 million shares valued at $68.5 million, while Perceptive Advisors LLC maintains 12.59 million shares worth about $48.9 million. Vanguard Capital Management and Clearstead Advisors, LLC recently opened new positions, acquiring 2.55 million and 2.33 million shares, respectively, with values of $9.88 million and $9.04 million. Comprehensive Financial Management LLC holds 2.21 million shares valued at $8.57 million.
Analysts Set New Price Targets
Analysts have recently weighed in on Nautilus Biotechnology. On February 27, 2026, Guggenheim maintained its "buy" rating with a price target of $4. Goldman Sachs previously downgraded the stock to "sell" with a target of $1.75 on December 8, 2024. Morgan Stanley maintained a "hold" rating with a $5 target on July 31, 2024.
Bottom Line
Insider buying activity at Nautilus Biotechnology, including significant purchases by Matthew Posard and others, highlights ongoing interest in the company. Institutional investors are also adjusting their positions, with some opening new stakes. Analysts' mixed ratings suggest varying expectations for the company's future performance. As always, 13F filings and insider transactions offer a retrospective look at holdings and may not reflect current positions.
Get Nautilus Biotechnology, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NAUT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.